The device was the first approved nonpharmacologic treatment for postmenopausal women with low bone density. It has not been tested for ability to reduce fractures.
For men with hypogonadism and low prostate cancer risk, TRT didn't increase the risk for prostate adverse events, said a new analysis likely to inform decision-making.